Orotecan (VAL-413)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Orotecan (VAL-413), covering 2025-09-23 to 2025-09-23. Get the full timeline:
Most recent: Clinical Trial Update: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors [Phase 1]